# US 2008/0188554 A1 · Methods of treating avian hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188554 A1
- Document ID: US20080188554A1
- Status: Published application
- Kind: A1
- Application number: 11/961,881
- Filed: 2007-12-20
- Published: 2008-08-07
- Earliest claimed: 2006-12-26
- Assignees: The Regents of the University of California Office of Technology Transfer; Texas A&M University
- Inventors: Bruce D. Hammock; Todd R. Harris; Christophe Morisseau; Rosemary L. Walzem
- Web page: https://patentgrep.com/patent/US20080188554A1

## CPC

- A61K 31/558: having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- C12N 9/14: Hydrolases (3)
- C12Y 303/0201: Soluble epoxide hydrolase (3.3.2.10)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides methods of treating avian pulmonary hypertension syndrome by administering to an avian subject a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase (“sEHI”), alone or co-administered in combination with a cis-epoxyeicosantrienoic acid (“EET”). The invention also provides nucleic acid and amino acid sequences of an avian soluble epoxide hydrolase.

## Claims

### Claim 1

A method of inhibiting or preventing pulmonary hypertension syndrome or a symptom thereof in an avian subject in need thereof, said method comprising administering to said avian subject an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”), thereby inhibiting pulmonary hypertension syndrome or said symptom thereof in said avian subject.

### Claim 2 (depends on 1)

The method of claim 1 comprising further co-administering a cis-epoxyeicosantrienoic acid (“EET”).

### Claim 3 (depends on 1)

The method of claim 1, wherein the avian subject is of the Subclass Neognathae.

### Claim 4 (depends on 1)

The method of claim 1, wherein the avian subject is of the Order Galliformes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the avian subject is of the Family Phasianidae.

### Claim 6 (depends on 1)

The method of claim 1, wherein the avian subject is a chicken (Gallus).

### Claim 7 (depends on 1)

The method of claim 1, wherein the symptom thereof is pulmonary hypertension.

### Claim 8 (depends on 1)

The method of claim 1, wherein the symptom thereof is right-sided congestive heart failure.

### Claim 9 (depends on 1)

The method of claim 1, wherein the symptom thereof is hypoxemia.

### Claim 10

An isolated nucleic acid encoding a soluble epoxide hydrolase having at least 95% nucleic acid sequence identity to the nucleic acid sequence depicted in FIG. 1.

### Claim 11

An isolated soluble epoxide hydrolase having at least 95% amino acid sequence identity to the amino acid sequence depicted in FIG. 1.

### Claim 12 (depends on 11)

An isolated soluble epoxide hydrolase of claim 11 comprising the amino acid sequence depicted in FIG. 1.